Conference Presentation, Panel
Immunotherapy: The Silver Bullet Against Cancer?
Milken InstituteDr. Jonathan Simons, Jed Wolchuk, Pam Sharma, Dr. Charles Drake, Elliot Siegel, TJ Sharp, Mary, Dr. William Coley, Jim Allison, Keith Black, Don Coffey, Magic Johnson, Tom Frye, Eleanor Roosevelt, Adlai Stevenson, Dr. Howard Sewell, Carl June, Drew Pardola
- Future cancer treatment is projected to leverage the immune system to the extent that traditional chemotherapy may become obsolete, aiming to cure the disease with minimal collateral damage.
- Immunotherapies are expected to extend life by many years for patients regardless of specific tumor mutations, with combination strategies involving multiple immunotherapies, radiation, targeted inhibitors, chemotherapy, or hormonal therapy required for maximum efficacy.
- Specific efficacy predictions for blocking PD-1 and CTLA-4 include disease stabilization in at least 65 percent of patients and complete remissions in 15 to 20 percent of patients.
- If response rates for lung cancer match melanoma, approximately 40,000 annual patients could see a 20 percent response rate, with 20,000 surviving two to three years who would not have otherwise survived.
- Annual survival estimates suggest that ensuring every eligible melanoma patient receives ipilimumab could save between 1,500 and 1,700 lives, while follow-up data confirms some patients survive more than 10 years.
- Clinical development strategies anticipate the use of systematic, uniform approaches to test combination therapies in cancers not initially responsive to single agents, alongside small 12-patient trials to understand immune response biology.
- New therapeutic modalities such as T-cell CAR therapies, smart vaccines for immune-profiled cancers, and mechanisms to induce inflammation in non-inflammatory tumors are predicted to emerge, though solid tumor safety for CAR therapies remains a concern.
- Regulatory frameworks are expected to shift toward accepting the percentage of patients alive at two to three years as an alternative approval endpoint, with optimism for accelerated FDA approval of breakthrough medicines.
- Corporate strategies are shifting toward reprioritizing projects at the interface of immunology and oncology, with some large companies exiting cancer fields entirely.
- Funding and personnel risks include a potential exodus of an entire generation of physician scientists and researchers if NIH and NCI grants are not approved or if the peer review system fails to distinguish valid immunotherapy proposals from "fishing expeditions."
- Research funding challenges persist as companies face the difficulty of financing experimental agents while assuming approval outcomes before regulatory decisions are made.
- Institutional expectations include a turning point in the war on cancer defined by recent breakthroughs, necessitating courageous leadership to navigate early challenges and guide the field's future trajectory.